GRAIL Q1 2026: revenue $40.8M (up 28%), Galleri volume 56k+ (up 50%), net loss $93.2M

GRAIL, Inc.

2026-Q1 EPS reported -$2.29 revenue$40,785,000

Total revenue $40.8M (+28% YoY); Galleri revenue $39.8M (+37%); test volume >56,000 (+50%).
Net loss $93.2M, improved $13.0M (12%) vs Q1 2025; adjusted EBITDA $(79.9)M, improved 19%.
Adjusted gross profit $19.7M (+38% YoY); cash & equivalents $823.1M.
Plans to integrate Galleri into Epic EHR; new NHS-Galleri and PATHFINDER 2 data at ASCO 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

GRAIL, Inc. reported first quarter ended March 31, 2026 results: revenue $40.8 million, net income $(93.2) million.

Period: first quarter ended March 31, 2026
Revenue: $40.8 million
Net income: $(93.2) million
Result: reported results

Exact text from the filing

GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the first quarter of 2026. Total revenue in the first quarter grew 28% year over year to $40.8 million, and Galleri revenue grew 37% year-over-year to $39.8 million. Galleri test volume for the quarter grew 50% year-over-year to more than 56,000. Net loss for the quarter was $93.2 million.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

GRAIL, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-26-030495

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.